BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Up 200.9% in May

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 594,279 shares, an increase of 200.9% from the May 14th total of 197,532 shares. Currently, 7.5% of the shares of the company are short sold. Based on an average trading volume of 38,808,369 shares, the short-interest ratio is currently 0.0 days.

Insider Activity

In other news, Director Reuven Yeganeh sold 530,000 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $5.00, for a total transaction of $2,650,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 21.80% of the company’s stock.

Institutional Investors Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC acquired a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX as of its most recent SEC filing. Hedge funds and other institutional investors own 40.57% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered shares of BiomX from a “buy” rating to a “hold” rating in a research report on Monday, March 9th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, BiomX has an average rating of “Hold” and an average target price of $26.00.

BiomX Stock Down 24.2%

NYSEAMERICAN PHGE traded down $0.17 during trading hours on Friday, hitting $0.54. The company’s stock had a trading volume of 13,015,283 shares, compared to its average volume of 17,731,742. The stock has a fifty day moving average of $1.32 and a 200 day moving average of $3.18. BiomX has a twelve month low of $0.36 and a twelve month high of $14.71. The firm has a market capitalization of $5.98 million, a P/E ratio of -0.17 and a beta of 1.18.

BiomX (NYSEAMERICAN:PHGE) last issued its earnings results on Wednesday, May 20th. The company reported $7.38 EPS for the quarter. On average, analysts predict that BiomX will post -5.85 earnings per share for the current year.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.